Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Henry E.

Dyax Corp. (NASDAQ:DYAX) announced today that it has entered into a committed equity financing facility under which it may sell up to $50 million of its common stock to Azimuth Opportunity, Ltd. over an 18-month period.

Dyax Corp. (NASDAQ:DYAX) announced today the completion of its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for approval of Dyax's lead product candidate DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE).

Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Henry E.

Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Henry E.